other material
confidence high
sentiment positive
materiality 0.85
Silence Therapeutics reports positive Phase 2 SANRECO topline: 88% vs 19% responder rate
Silence Therapeutics plc
- Primary endpoint met: 88% clinical responders on divesiran vs 19% placebo (p<0.0001); placebo-adjusted 69%.
- Both dose groups strong: 93.8% response at Q6W, 81.3% at Q12W in 48 phlebotomy-dependent PV patients.
- Phlebotomy rate cut to 0.2 vs 2.1 per patient (p<0.0001); hematocrit control and MPN-SAF TSS improved.
- Well tolerated, no new safety findings; two grade 1 anemia cases. Phase 3 Q12W vs placebo expected 1H'27.